Welcome back to the Psychedelic Invest week in review. Here are the stories that moved the psychedelic sector during the week of April 13–19, 2026 — from clinical readouts to regulatory shifts and the capital flowing through the space.
Compass Pathways plc (CMPS): Compass opens U.S. grant program to build COMP360 provider training
Compass Pathways invited U.S. organizations to apply, from April 14 to May 14, for grants to develop healthcare-provider training for delivering COMP360 psilocybin therapy if approved. The company expects to fund up to three organizations to build foundational psychedelic and COMP360-specific training modules. The move is part of Compass's commercial readiness effort ahead of a targeted end-of-2026 launch preparation for treatment-resistant depression.
Source: businesswire.com
Definium Therapeutics, Inc. (DFTX): Definium flags three Phase 3 DT120 readouts coming in 2026
Definium Therapeutics (the former MindMed) outlined a cluster of near-term catalysts for its DT120 (MM120, an LSD-based ODT) program, teasing three pivotal Phase 3 topline readouts. The company pointed to the Emerge study in major depressive disorder in late Q2 2026, followed by the Voyage and Panorama studies in generalized anxiety disorder in Q3 2026. The timeline positions Definium as one of the busiest late-stage psychedelic pipelines heading into mid-2026.
Source: marketbeat.com
U.S. Federal Government (policy): Trump signs executive order to accelerate psychedelic treatments
President Trump signed an executive order titled 'Accelerating Medical Treatments for Serious Mental Illness,' directing the FDA to prioritize review of psychedelic compounds and instructing the DEA and other agencies to ease research restrictions. The order named compounds such as psilocybin and ibogaine, allocated roughly $50 million toward federal-state research collaboration, and set the stage for expanded access pathways. Psychedelic equities rallied sharply the following trading day.
Source: whitehouse.gov
Compass Pathways plc (CMPS): Compass commends White House psychedelics executive order
Compass Pathways issued a statement welcoming the executive order, with CEO Kabir Nath framing it as recognition of the urgency of the mental health crisis and the potential of FDA-approved psychedelics. The company reiterated that it is running the largest classic-psychedelic trials to date and has posted two positive Phase 3 readouts for COMP360 in treatment-resistant depression. As the sector's most advanced developer, Compass is positioned to benefit directly from faster FDA review pathways.
Source: ir.compasspathways.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.